Diasorin S.p.a. · MIL:DIA

Diasorin — H1 2018 Earnings Presentation

12 slides from Diasorin's earnings presentation, Aug 2, 2018

  1. Slide 1: Q2 and H1 2018 Results

    Q2 and H1 2018 Results DIASORIN SPA August 2, 2018

  2. Slide 2: Disclaimer

    Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela

  3. Slide 3: Highlights

    Highlights COMPANY GUIDANCE Q2’18 H1’18 @ curr @ CER @ curr @ CER FY 2018 FY 2019 REVENUES €/mln 166.7 (*) +3.0% +6.7% €/mln 331.2 (*) +3.7% +9.0% 3-years plan guidance REVENUES ~ +9% at CER vs 2017 (°) confirmed CLIA EX VIT D 25 OH +4.8% +7.6% +6.9% +10.5% from ~ +11% at CER VIT D 25 OH -9.1% -3.9%

  4. Slide 4: Q2 and H1 2018 revenues growth

    Q2 and H1 2018 revenues growth Q2’18 vs. Q2’17 H1’18 vs. H1’17 Q2’18 vs. Q2’17 H1’18 vs. H1’17 @ curr EUROPE & AFRICA +14.1% +15.2% Total Group revenues +3.0% +3.7% Growth driven by Siemens’ ELISA business acquisition and @ CER +6.7% +9.0% Germany +22.0% +22.7% CLIA ex Vit D tests. Negative Vitamin

  5. Slide 5: H1 2018 revenues breakdown

    H1 2018 revenues breakdown by geography by technology Instruments & other revenues H1’17 H1’17 North America 11.7% 32.4% Molecular diagnostic tests Europe & Africa 9.6% 42.7% CLIA tests 66.8% ELISA tests 11.9% Asia Pacific 17.6% Latin America 7.3% H1’18 (*) H1’18 (*) Instruments & other revenues Nor

  6. Slide 6: Installed base expansion

    Installed base expansion 7,398 7,501 7,623 +239 3,518 +116 3,634 +123 3,757 LAS 3,880 -13 3,867 -1 3,866 -14 @ Dec 31, 2017 @ March 31, 2018 @ June 30, 2018 Q2 and H1 2018 Results 6

  7. Slide 7: Q2 and H1 2018 profitability profile

    Q2 and H1 2018 profitability profile Q2’17 Q2’18 Change % H1’17 H1’18 Change % EBITDA (€/MLN) 63.7 64.9 +1.9% 126.2 128.2 +1.6% @ CER +6.5% +7.9% EBITDA MARGIN 39.4% 38.9% -44 bps 39.5% 38.7% -82 bps @ CER 39.3% -10 bps 39.1% -40 bps H1’18 EBITDA upward compared to H1’17 notwithstanding: • some one-

  8. Slide 8: Financial schemes

    Financial schemes 8

  9. Slide 9: Income Statement

    Income Statement Q2 Change H1 Change Data in € million 2017 2018 amount % 2017 2018 amount % Net revenues 161.8 166.7 +4.9 +3.0% 319.3 331.2 +11.9 +3.7% Gross profit 111.3 115.6 +4.4 +3.9% 219.2 226.8 +7.6 +3.5% Gross Margin 68.8% 69.4% +60 bps 68.7% 68.5% -16 bps S&M (30.3) (33.3) -3.0 +9.9% (60.1)

  10. Slide 10: Balance Sheet

    Balance Sheet Data in € million 12/31/17 06/30/18 Change Goodwill and intangibles assets 344.4 356.1 +11.7 Property, plant and equipment 92.3 89.7 -2.6 Other non-current assets 23.8 24.9 +1.1 Net working capital 190.7 211.9 +21.1 Assets held for sale 4.0 - -4.0 Other non-current liabilities (62.5) (

  11. Slide 11: Cash Flow Statement

    Cash Flow Statement Q2 H1 Data in € million Change Change 2017 2018 2017 2018 Cash and cash equivalents at the beginning of the period 172.8 172.3 -0.4 130.5 159.3 +28.9 Operating activities 25.8 50.8 +25.0 77.0 88.4 +11.4 Investing activities (9.1) (10.9) -1.8 (17.1) (21.0) -3.8 Financing activitie

  12. Slide 12: Slide 12

DiaSorin — H1 2018 Earnings Presentation on 6ix